This reference antibody, analogous to tozorakimab, is intended for research purposes only and not for therapeutic use in humans. It specifically targets and neutralizes interleukin-33 (IL-33), an upstream cytokine central to type 2 inflammation pathways. Primarily studied in models of moderate to severe asthma, especially in eosinophilic phenotypes or corticosteroid-dependent cases, it helps investigate reductions in airway inflammation, exacerbation frequency, and corticosteroid dependence. It is also relevant for research into other IL-33-driven conditions, including chronic obstructive pulmonary disease (COPD) and nasal polyps. Preclinical and translational studies demonstrate potential improvements in lung function and inflammatory markers, supporting its utility as a tool for targeted biologic research in respiratory diseases.